×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:ARNA

Arena Pharmaceuticals (ARNA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$99.99
$99.99
50-Day Range
$93.13
$99.99
52-Week Range
$45.50
$100.00
Volume
107 shs
Average Volume
1.56 million shs
Market Capitalization
$6.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.55

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Arena Pharmaceuticals logo

About Arena Pharmaceuticals

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ARNA
CUSIP
04004710
Employees
448
Year Founded
1977

Sales & Book Value

Annual Sales
$50 thousand
Price / Sales
123,305.67
Book Value
$10.94 per share

Profitability

Net Income
$-616.43 million
Pretax Margin
-1,141,542.63%

Debt

Price-To-Earnings

Miscellaneous

Free Float
60,173,000
Market Cap
$6.17 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
5/27/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.54 out of 5 stars

Medical Sector

1020th out of 1,424 stocks

Pharmaceutical Preparations Industry

504th out of 681 stocks

Analyst Opinion: 1.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

Is Arena Pharmaceuticals a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last twelve months. There are currently 10 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Arena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares.
View analyst ratings for Arena Pharmaceuticals
or view top-rated stocks.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.21) EPS for the quarter, missing the consensus estimate of ($2.53) by $0.68. During the same period in the previous year, the company posted ($1.69) EPS.
View Arena Pharmaceuticals' earnings history
.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals's stock reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

10 brokers have issued twelve-month price targets for Arena Pharmaceuticals' shares. Their forecasts range from $71.00 to $105.00. On average, they anticipate Arena Pharmaceuticals' stock price to reach $95.60 in the next twelve months. This suggests that the stock has a possible downside of 4.4%.
View analysts' price targets for Arena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arena Pharmaceuticals' key executives?
Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi M.B.A., Pres & CEO (Age 54, Pay $1.22M)
  • Ms. Laurie D. Stelzer, Exec. VP & CFO (Age 54, Pay $630.76k)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 54, Pay $692.82k) (LinkedIn Profile)
  • Dr. Christopher H. Cabell FACC, M.D., MHS, Advisor
  • Mr. Robert Lisicki, Exec. VP & Chief Commercial Officer (Age 54, Pay $686.63k)
  • Dr. Douglas A. Bakan Ph.D., Exec. VP of Technical Operations
  • Dr. Lamine Mbow Ph.D., Sr. VP & Chief Scientific Officer
  • Megan E. Knight, Director of Investor Relations
  • Patrick Malloy, VP of Investor Relations & Corp. Communications
  • Mr. Michael E. Paolucci, Exec. VP of HR (Age 62)
What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Glassdoor.com. Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (0.00%), TIG Advisors LLC (0.00%), Verition Fund Management LLC (0.00%), Group One Trading L.P. (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Manmeet Singh Soni, Manmeet Singh Soni, Robert Lisicki, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals
.

Which major investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Verition Fund Management LLC, Group One Trading L.P., TIG Advisors LLC, Walleye Trading LLC, Cutler Group LP, Goldman Sachs Group Inc., and Harvest Management LLC. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Jayson Donald Alexander Dallas, and Robert Lisicki.
View insider buying and selling activity for Arena Pharmaceuticals
or view top insider-selling stocks.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $99.99.

How much money does Arena Pharmaceuticals make?

Arena Pharmaceuticals has a market capitalization of $6.17 billion and generates $50 thousand in revenue each year. The biopharmaceutical company earns $-616.43 million in net income (profit) each year or ($10.13) on an earnings per share basis.

How many employees does Arena Pharmaceuticals have?

Arena Pharmaceuticals employs 448 workers across the globe.

When was Arena Pharmaceuticals founded?

Arena Pharmaceuticals was founded in 1977.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at (858) 453-7200, via email at [email protected], or via fax at 858-453-7210.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.